Clinical relevance of inhaled corticosteroids and HPA axis suppression


      Although hypothalamic-pituitary-adrenal (HPA) axis suppression has traditionally been viewed as an adverse event after long-term administration of corticosteroids, this effect can also be used to compare the potency of different inhaled corticosteroids. However, various factors such as the dose, frequency of administration, treatment duration, study population (patients with asthma versus normal volunteers), and prior systemic steroid therapy influence adrenal suppression with inhaled corticosteroids. The different adrenal function tests available and the results produced with these tests also must be considered along with the clinical relevance of such results. Whereas low doses of inhaled corticosteroids are likely to cause minimal or no HPA axis suppression, long-term high-dose inhaled corticosteroid use may result in significant suppression by effectively replacing endogenous steroid production. The risk of acute adrenal insufficiency in patients taking low/medium-dose inhaled corticosteroids is minimal, but patients receiving long-term high-dose treatment may require supplementary systemic steroids during stress challenges, especially if they have previously received long-term systemic steroid treatment. (J Allergy Clin Immunol 1998:101;S447-50.)



      ACTH (Adrenocorticotrophic hormone), AUC (Area under the curve), BDP (Beclomethasone diproprionate), BUD (Budesonide), FP (Fluticasone propionate), HPA (Hypothalamic-pituitary-adrenal)
      To read this article in full you will need to make a payment


        • Barnes PJ.
        Inhaled glucocorticoids for asthma.
        N Engl J Med. 1995; 332: 868-875
        • Padfield PL
        • Teelucksingh S.
        Inhaled corticosteroids: the endocrinologist's view.
        Eur Respir Rev. 1993; 3: 494-500
        • Tordjman K
        • Jaffe A
        • Grazas N
        • Apter C
        • Stern N.
        The role of low dose (1 microgram) adrenocorticotrophin test in the evaluation of patients with pituitary diseases.
        J Clin Endocrinol Metab. 1995; 80: 1301-1305
        • Grahnen A
        • Eckernas SA
        • Brundin RM
        • Ling-Andersson A.
        An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers.
        Br J Clin Pharmacol. 1994; 38: 521-525
        • Volovitz B
        • Amir J
        • Malik H
        • Kauschansky A
        • Varsano I.
        Growth and pituitary-adrenal function in children with severe asthma treated with inhaled budesonide.
        N Engl J Med. 1993; 329: 1731-1733
        • Brown PH
        • Blundell G
        • Greening AP
        • Crompton GK.
        Hypothalamo-pituitary-adrenal axis suppression in asthmatics inhaling high dose corticosteroids.
        Respir Med. 1991; 85: 501-510
        • Brown PH
        • Blundell G
        • Greening AP
        • Crompton GK.
        High dose inhaled steroid therapy and the cortisol stress response to acute severe asthma.
        Respir Med. 1992; 86: 495-497
        • Toogood JH
        • Jennings B
        • Baskerville J
        • Lefcoe NM.
        Personal observations on the use of inhaled corticosteroid drugs for chronic asthma.
        Eur J Respir Dis. 1984; 65: 321-338
        • Kehlet H
        • Binder C.
        Adrenocortical function and clinical course during and after surgery in unsupplemented glucocorticoid-treated patients.
        Br J Anesth. 1973; 45: 1043-1048